Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
Nicholas SchwabTilman Schneider-HohendorfBéatrice PignoletFlorence BucciarelliLise ScandellaJonathan CironDamien BiottiChristine Lebrun-FrenayGuillaume MatheyPierre ClavelouJean PelletierPatrick OstkampIngrid MeinlSusanne WindhagenLuisa KlotzCatharina C GrossSven G MeuthFlorian DeisenhammerDavid BrassatHeinz Wiendlnull nullPublished in: Neurology (2019)
Keyphrases